ROUNDTABLE: Treating HCV-infected patients in 2019
What are the initial steps to take when characterizing a hepatitis C virus (HCV) infection? What are the variables that influence antiviral choice? In the first video of our 4-part video series, a panel of experts discuss their approaches to characterizing fibrosis, selecting therapy and determining treatment duration, and assuring adherence. Stay tuned for our entire series that examines the key issues that impact effective management of HCV-infected patients in 2019, including assuring access to care, managing difficult-to-treat populations, and determining the duration of treatment. For additional resources for both patients and care providers, please visit the American Gastroenterological Association (AGA) GI Patient Center.
Disclosure: The faculty received modest honoraria from Frontline Medical Communications for their participation in this roundtable and maintained complete editorial control over all content presented. The views of the faculty do not necessarily reflect those of Frontline Medical Communications or the American Gastroenterological Association (AGA).
This video roundtable was produced by the specialized content division of Frontline Medical Communications, publisher of GI & Hepatology News.
The editorial staff of GI & Hepatology News was not involved in developing the video roundtable.
Dr. Lim reports receiving a research grant to his institution (Yale University) from Gilead.
Dr. Bernstein reports being an advisory board member and consultant for Abbvie and Gilead. He also reports receiving research support from Gilead.
Dr. Brown reports being a consultant for and receiving research grants from Abbvie, Bristol-Myers Squibb, Gilead, and Merck.